CAJ | 학술논문

精准医疗是一种基于病人特定分子标志物的医疗模式，不同于目前针对一般病人的循证医学模式。简要介绍了精准医疗的发展历史和美国的精准医疗计划，提出对制药行业的挑战主要在于：新药产品研发的复杂程度加大、较小的市场容量下研发投入难以回报、配套政策的滞后，给制药行业带来的机会在于：疾病细分导致药物创新需求增加、老药和失败药物面临重生的机遇、中小企业竞争的优势上升、延伸产业发展空间巨大，并针对性地提出了发展策略和建议。
정준의료시일충기우병인특정분자표지물적의료모식，불동우목전침대일반병인적순증의학모식。간요개소료정준의료적발전역사화미국적정준의료계화，제출대제약행업적도전주요재우：신약산품연발적복잡정도가대、교소적시장용량하연발투입난이회보、배투정책적체후，급제약행업대래적궤회재우：질병세분도치약물창신수구증가、로약화실패약물면림중생적궤우、중소기업경쟁적우세상승、연신산업발전공간거대，병침대성지제출료발전책략화건의。
Precision medicine is a medical model based on the specific molecular markers of the patients, and it is different from the evidence-based medicine for “average patient”. The histories of precision medicine and “precision medicine initiative” of USA were introduced briefly. It is suggested that the possible challenges for pharmaceutical industry including the complexity of the new product development, the investment return bottleneck because of market capacity, and the constraints from related policies. The opportunities for the pharmaceutical industry will be the large number of diseases for drug innovation, rebirth chance for failure or older drugs, more competitive advantages for the small and medium sized enterprises, and further space for industrial development. Several suggestions are targeted given.